Clondalkin Group, an international producer of flexible and specialist packaging products, has agreed to acquire the Printed Components business of Catalent. Terms of the transaction were not disclosed, and closing is subject to receipt of regulatory approval. At the closing, Clondalkin and Catalent will enter into a long-term supply agreement which ensures that Catalent will continue to be able to provide customers of its commercial packaging business with printed components.
With annual sales in excess of $100 million (€75 million), Printed Components manufactures secondary packaging products for the pharmaceutical and healthcare markets at four production locations in the United States, Puerto Rico and Ireland.
Clondalkin, which has annual sales in excess of $1.1 billion (€850 million) and more than 40 production locations in 10 countries throughout Europe and the USA, is a supplier of secondary packaging products to the pharmaceutical and healthcare markets with 14 pharmaceutical packaging approved production plants in Europe and North America.
Barry Russell, president of Catalent’s Medication Delivery Solutions business, says, “We are pleased that Clondalkin Group has agreed to acquire the business. We believe that Clondalkin will continue to build upon the business’ legacy of excellent service and high quality. We also believe that the commitment Clondalkin Group has demonstrated to the industry aligns well with our approach of tailoring unique product supply solutions for our customers.”
Norbert McDermott, Clondalkin Group’s Chief Executive, notes, “We are looking forward to acquiring Catalent’s Printed Components business and developing our supply partnership with Catalent. Our focus in pharmaceutical and healthcare secondary packaging is to deliver market leading innovative products and services to our customers. The acquisition takes our customer service offering to a new level of unrivalled capabilities and possibilities in location, technology and product choices.”
He adds that the acquisition “will increase our pharmaceutical and healthcare activities to approximately $340 million (€257 million) and to 28 percent of our annual sales.”